6 Strong Buys Breaking Near 52-Week Highs
Johnson & Johnson (JNJ)
Background: Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the health care field worldwide. Founded in 1886, it is based in New Brunswick, N.J. Johnson & Johnson trades an average of 10 million shares per day with a market cap of $191 billion.
52-Week High: $69.75 TheStreet'sJim Cramer writes about Johnson & Johnson in The Market's Unheeded Flashing Signals
More than half the analysts covering Johnson & Johnson rate it as a buy or strong buy. Fifteen of the 26 analysts covering the company give a buy recommendation. Eleven analysts rate it a hold, and none of the analysts recommend selling. The stock increased in value 11% during the last year, and the average analyst target price for Johnson & Johnson is $73.80. This stock currently has an annualized dividend of $2.44, yielding 3.5%. The yield alone almost justifies an allocation of some capital. Not everyone is convinced buying is the correct choice, though. Along with the 11 analysts with hold ratings, short-sellers are taking an interest. With short interest above 5%, investors will want to monitor changes to know whether short-sellers turn up the warning signals. Otherwise, the current 6% of the float short is relatively small and not a major concern. From a technical perspective, the chart on Johnson & Johnson looks interesting. The widely followed moving averages and price action are strongly bullish. Johnson & Johnson shareholders have to be pleased right now. Don't be surprised to see Johnson & Johnson over $70 a share, and within 10 to 15 days.Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
